Ona Therapeutics

📂 Healthtech📍 Barcelona🗓️ Founded: 2019

Barcelona biotech spun out of IRB and ICREA developing first-in-class ADCs for treatment-resistant cancers; it raised an $86.6M Series B in June 2026.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

About Ona Therapeutics

Ona Therapeutics was founded in 2019 in Barcelona as a spin-off of IRB Barcelona and ICREA and is based at the Barcelona Science Park. Its scientific roots lie in Salvador Aznar Benitah's work on metastasis-initiating cells and their dependence on lipid metabolism; co-founder Valerie Vanhooren is the CEO. In 2020 the company closed a EUR 30 million Series A led by Asabys Partners, with Alta Life Sciences, Ysios Capital, Fund+ and Bpifrance, to take into the clinic a biologic designed to block the uptake of saturated fats by metastatic cells. The company looks different today. Recent sources describe Ona as a biopharmaceutical business building first-in-class antibody-drug conjugates (ADCs) for cancers that have become resistant to existing treatments. It starts from a patient-driven discovery platform: samples from treatment-refractory tumors are mined for tumor-specific antigens and epitopes, which are then turned into ADCs using engineered antibodies and validated linker-payload technology. The lead program, ONA-255, is in a Phase 1a trial; by late September 2026 more than half of the planned patients had been enrolled in the multicenter, open-label dose-escalation study covering HR-positive/HER2-negative advanced breast cancer and metastatic gastric cancer. ONA-389, aimed at colorectal and hepatocellular cancer, is in IND-enabling studies and is expected to enter the clinic in the second half of 2027, while ONA-418 is built around dual-linker, dual-payload technology. Financing has tracked that shift. In October 2025 a EUR 10 million investment led by SICC Innvierte (CDTI) was announced alongside existing shareholders; on 4 June 2026 came an oversubscribed $86.6 million Series B (about EUR 74.2 million), co-led by Columbus Venture Partners and Mérieux Equity Partners with COFIDES, Korys and the existing investors. The money is earmarked for ONA-255 toward clinical proof of concept and for ONA-389 toward first-in-human studies. The management bench was built for the clinical phase too: Antoine Yver became board chair in October 2025, Aleix Prat was named Chief Medical Officer in September 2026 and Jutta Amersdorffer is Chief Development Officer. Ona says it retains worldwide commercial rights to all of its assets. Why it matters: the round puts Ona among Spain's largest financings of the first half of 2026 and shows that a Catalan academic spin-off can reach the clinic on European public and private capital while staying independent. The usual biotech caveat applies: no clinical data have been published, and the company's value will depend on how the Phase 1 results for ONA-255 read out.

The Story

Founded in 2019 as a spin-off of IRB Barcelona and ICREA by Valerie Vanhooren and Salvador Aznar Benitah, building on his research into metastasis-initiating cells and the role of lipids.

How Ona Therapeutics works

Business Model

Clinical-stage oncology biotech that develops proprietary assets without commercial revenue, funded by venture rounds and public investors. It states that it retains worldwide commercial rights to all of its assets.

Revenue Model

No product revenue: the company is at an early clinical stage. The sources show no out-licensing deals, only an in-licensing option on Biocytogen antibodies (December 2023). How the company intends to monetize its assets is not stated.

Products & Services

Key Products

  • ONA-255 (first-in-class ADC, breast and gastric cancer, Phase 1a)
  • ONA-389 (first-in-class ADC, colorectal and hepatocellular cancer, IND-enabling)
  • ONA-418 (dual-linker, dual-payload ADC, preclinical)
  • Patient-driven target discovery platform

Core Use Cases

  • Advanced HR-positive/HER2-negative breast cancer
  • Metastatic gastric cancer
  • Colorectal cancer and hepatocellular carcinoma
  • Discovery of tumor antigens from refractory patient samples

Market & Clients

Key Customers

Cancer patients with treatment-resistant tumors, reached through clinical centers and oncologists; potentially pharma partners later, none announced so far.

Geographic Presence

ES

How Ona Therapeutics competes

Competitive Advantages

  • Patient-driven discovery platform built on samples from refractory tumors
  • First-in-class ADC programs, with ONA-255 already in Phase 1a
  • Dual-linker, dual-payload technology in the pipeline (ONA-418)
  • Worldwide commercial rights retained on all assets
  • Scientific and clinical network tied to IRB Barcelona, ICREA and Clínic Barcelona

How Ona Therapeutics grows

Growth Strategy

Take ONA-255 to clinical proof of concept, advance ONA-389 toward first-in-human studies (second half of 2027) and develop ONA-418, using the Series B and the 2025 investment.

Distribution Model

No commercial distribution yet: the company is in clinical development and any approved product would need a route to market that the sources do not define.

Moat (Defensibility)

Biological know-how on resistant tumors and data from patient samples, plus the intellectual property on its ADCs and discovered antigens, supported by deals such as the Biocytogen antibody option.

Regulatory Context

Oncology biologics in trials: each program needs clinical trial authorizations and, if successful, regulatory approval before commercialization; ONA-389 is still in IND-enabling studies.

Key Risks

  • Clinical risk: ONA-255 is in Phase 1a and no clinical data have been published
  • Pipeline concentrated in a few programs, with ONA-389 not yet in the clinic
  • Heavy capital needs for later development phases
  • Competition from large pharma groups in oncology ADCs
  • Future monetization route is not defined in the sources

Strategic Insights

  • The positioning has shifted: in 2020 the thesis was to block saturated-fat uptake by metastatic cells, while today's pipeline is ADCs derived from refractory tumor samples.
  • The Series A backers (Asabys, Alta Life Sciences, Ysios, Fund+, Bpifrance) are still on the cap table in the Series B, joined by new funds such as COFIDES and Korys.
  • Spanish public capital features throughout: CDTI via SICC Innvierte led the EUR 10 million investment in 2025 and joined the Series B alongside COFIDES.

Funding & Investors

Funding Rounds

  • 2026 - Series B: $86.6M / circa €74.2M
    Lead: Columbus Venture Partners, Mérieux Equity Partners
  • 2025 - Venture round (round name not specified): €10M
    Lead: SICC Innvierte (CDTI)
  • 2020 - Grant (Eurostars-2, LIPOLOGIC consortium):
  • 2020 - Series A: €30M
    Lead: Asabys Partners

Key Investors

Columbus Venture PartnersMérieux Equity PartnersCOFIDESKorysAsabys PartnersAlta Life SciencesYsios CapitalBpifranceCDTI (through SICC Innvierte)FundPlus NV (Fund+)

Founding Team

Founders

Valerie VanhoorenCo-founder and CEO
Salvador Aznar BenitahCo-founder

Key Executives

  • Aleix Prat - Chief Medical Officer
  • Jutta Amersdorffer - Chief Development Officer
  • Haijun Sun - Chief Scientific Officer
  • Julià Mesquida - Chief Financial Officer

Key Metrics

Series B funding$86.6M / circa €74.2M (2026)
Series A funding€30M (2020)
Phase 1a enrollment (ONA-255)More than 50% of planned patients enrolled (2026)
Founded2019 (2019)

Lessons from Ona Therapeutics

  • Before entering the clinic, Ona built its clinical leadership: a board chair with oncology drug-development experience (October 2025) and a Chief Medical Officer (September 2026).
  • A scientific thesis can evolve without losing backers: the 2020 investors stayed on after the move to ADCs.
  • Pairing the financing with clinical progress (over 50% enrolled in Phase 1a) gives new investors a concrete data point to underwrite.

Similar Startups

📍 Barcelona

GYALA THERAPEUTICS SL

Spin-off of Hospital Clínic de Barcelona and IDIBAPS developing next-generation treatments for blood cancers.

Read Analysis
📍 Barcelona

Integra Therapeutics

Barcelona spin-off of Pompeu Fabra University developing FiCAT, a gene-writing platform that pairs CRISPR-Cas precision with an engineered piggyBac transposase. Preclinical, aimed at CAR-T and genetic diseases.

Read Analysis
📍 Barcelona

Pragmatech

Pragmatech has developed an AI platform for dermatological image analysis that assists physicians in recognising suspicious skin lesions for early detection of melanoma and other skin cancers.

Read Analysis

Sources

🎙️ Scalable Podcast — European startup stories · 🇮🇹 in Italian
Spotify 🎧 Apple